GSK and MVV launch malaria medicine in Brazil and Thailand
08 Jul 2024
Preview
Source: Pharmaceutical Technology
The new single-dose medicine prevents the relapse of Plasmodium vivax malaria. Credit: sun ok / Shutterstock.
GSK and Medicines for Malaria Venture (MMV)Malaria Venture (MMV) have announced the launch of a new single-dose medicine, tafenoquine, to prevent the relapse of Plasmodium vivax (P. vivax) malaria in malaria-endemic countries Brazil and Thailand.
Tafenoquine is co-administered with chloroquine, for radical cure.
An antimalarial drug, tafenoquine is an 8-aminoquinoline that targets the liver stage of P. vivax malaria.
When used with chloroquine, which addresses the blood-stage infection, tafenoquine can effectively treat both stages of the disease.
But tafenoquine can cause acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiencyglucose-6-phosphate dehydrogenase (G6PD) deficiency.
See Also:Ascentage Pharma’s olverembatinib approved in Macau for leukaemia
Preview
Source: Pharmaceutical Technology
NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Preview
Source: Pharmaceutical Technology
As a result, a G6PD test is essential before the drug can be prescribed.
The Ministries of Health in Thailand and Brazil have conducted feasibility studies on the routine use of tafenoquine after point-of-care G6PD testing.
These studies, supported by MMV, have been instrumental in their decisions to adopt this new anti-malarial strategy.
In Brazil, the urgency of the public health emergency in the Yanomami Special Indigenous Health District, where P. vivax malaria is particularly prevalent, led to the accelerated approval of tafenoquine in March 2024.
Tafenoquine has now received approvals in Australia, Brazil, Colombia, Ethiopia, Guyana, Peru, the Philippines and the US.
GSK chief global health officer Thomas Breuer stated: “The news underscores GSK’s long-standing commitment to malaria and we are proud that tafenoquine, co-administered with chloroquine, the first radical cure medicine for P. vivax malaria, is now launched in both Brazil and Thailand, taking us another step closer to our shared goal of eliminating malaria.
“Working together with MMV and PATH [the Program for Appropriate Techonology in Health] through the Partnership for Vivax Elimination to optimise this new treatment option has been fundamental to countries being able to introduce this new tool.”
In June 2024 GSK received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Omjjara (momelotinib) to treat patients with myelofibrosis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.